Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 15;25(1):1783.
doi: 10.1186/s12889-025-22977-w.

Cost-effectiveness of low-dose CT screening for non-smokers with a first-degree relative history of lung cancer

Yin Liu  1 , Xiaoli Guo  1 , Huifang Xu  1 , Xiaoyang Wang  1 , Hongwei Liu  1 , Hong Wang  1 , Ruihua Kang  1 , Qiong Chen  1 , Ranran Qie  1 , Mengfei Zhao  1 , Cheng Cheng  1 , Liyang Zheng  1 , Shuzheng Liu  1 , Youlin Qiao  2   3 , Shaokai Zhang  4
Affiliations

Cost-effectiveness of low-dose CT screening for non-smokers with a first-degree relative history of lung cancer

Yin Liu et al. BMC Public Health. .

Abstract

Background: Lung cancer is the leading cause of cancer-related deaths worldwide, with non-smokers in China accounting for over 40% of cases. Despite the proven efficacy of low-dose computed tomography (LDCT) in early detection and reduction of lung cancer mortality, the current paradigm of lung cancer screening, heavily focused on smoking status and age, may inadequately address the unique risk factors associated with non-smokers, particularly those with a family history of the disease. This study evaluates the cost-effectiveness of LDCT screening for non-smokers with a first-degree relative (FDR) history of lung cancer, a group at particularly high-risk.

Methods: We developed a state-transition Markov model to evaluate the incremental cost-effectiveness ratios (ICERs) of 16 screening strategies for a hypothetical cohort of 100,000 non-smoking individuals aged 50 with a FDR history of lung cancer, considering various starting ages (50, 55, 60, 65 years) and intervals (one-off, annual, biennial, triennial). The willingness-to-pay (WTP) threshold was set at three times China's 2022 per-capita GDP. Sensitivity analyses, scenario analyses and subgroup analysis by sex, were conducted.

Results: Compared to no screening, all strategies except one-off screening at age 50, were cost-effective for both sexes. Biennial LDCT starting at age 55 was found to be most effective, with an ICER of CNY 68,932/QALY for males, and CNY 80,056/QALY for females. This cost-effectiveness probability for this strategy was approximately 90% for both sexes. Sensitivity analyses indicated that annual screening at age 55 was optimal without discounting. For males, biennial at age 60 was optimal if the FDR-related odds ratio for lung cancer incidence was below 1.492. Triennial screening at age 55 was optimal for females at full adherence. Ignoring disutility from false-positive results, annual at age 55 was optimal for both sexes.

Conclusions: LDCT screening for non-smokers with a FDR history of lung cancer is cost-effective, especially biennial screening at 55. These findings support the development of more inclusive screening guidelines, which could enhance early detection and reduce mortality rates.

Keywords: Cost-effectiveness; LDCT screening; Lung Cancer; Modelling study; Non-smokers.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Cost-effectiveness frontiers for all 16 screening strategies. Incremental QALYs and incremental costs of intervention strategies are obtained for 100,000 individuals
Fig. 2
Fig. 2
Cost-effectiveness acceptability curves for all strategies. Intervention strategies that never have the highest probability of being cost-effective within the willingness-to-pay threshold of three-times per-capita GDP are represented in grey. QALY, quality-adjusted life years
Fig. 3
Fig. 3
Cost-effectiveness acceptability curves for all strategies at higher screening adherence rate or when disregarding potential LDCT-harms. Intervention strategies that never have the highest probability of being cost-effective within the willingness-to-pay threshold of three-times per-capita GDP are represented in grey. QALY, quality-adjusted life years
See this image and copyright information in PMC

References

    1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. - PubMed
    1. Global Cancer Observatory. International Agency for Research on Cancer. https://gco.iarc.fr/en. Accessed March 10, 2024.
    1. Fang Y, Li Z, Chen H, et al. Burden of lung cancer along with attributable risk factors in China from 1990 to 2019, and projections until 2030. J Cancer Res Clin Oncol. 2023;149(7):3209–18. - PMC - PubMed
    1. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409. - PMC - PubMed
    1. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced Lung-Cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503–13. - PubMed